Lysyl oxidase (LOX), a matrix cross-linking protein, is known to be selectively expressed and to enhance a fibrotic phenotype. A recent study of ours showed that LOX oxidizes the PDGF receptor-β (PDGFR-β), leading to amplified downstream signaling. Here, we examined the expression and functions of LOX in megakaryocytes (MK), the platelet precursors. Cells committed to the MK lineage undergo mitotic proliferation to yield diploid cells, followed by endomitosis and acquisition of polyploidy. Intriguingly, LOX expression is detected in diploid-tetraploid MKs, but scarcely in polyploid MKs. PDGFR-BB is an inducer of mitotic proliferation in MKs. LOX inhibition with β-aminopropionitrile (BAPN) reduces PDGFR-BB binding to cells, and downstream signaling, as well as its proliferative effect on the MK lineage. Inhibition of LOX activity has no influence on MK polyploidy. We next rationalized that in a system with an abundance of low ploidy MKs, LOX could be highly expressed and with functional significance. Thus, we resorted to GATA-1 low mice, where there is an increase in low ploidy MKs, augmented levels of PDGF-BB, and an extensive matrix of fibers. MKs from these mice display high expression of LOX, compared to control mice. Importantly, treatment of GATA-1 low mice with BAPN significantly improves the bone marrow fibrotic phenotype, and MK number in the spleen. Thus, our in vitro and in vivo data support a novel role for LOX in regulating MK expansion by PDGF-BB, and suggest LOX as a new potential therapeutic target for myelofibrosis.
Lysyl oxidase (LOX), a matrix cross-linking protein, is known to be selectively expressed and to enhance a fibrotic phenotype. A recent study of ours showed that LOX oxidizes the PDGF receptor-β (PDGFR-β), leading to amplified downstream signaling. Here, we examined the expression and functions of LOX in megakaryocytes (MK), the platelet precursors. Cells committed to the MK lineage undergo mitotic proliferation to yield diploid cells, followed by endomitosis and acquisition of polyploidy. Intriguingly, LOX expression is detected in diploid-tetraploid MKs, but scarcely in polyploid MKs. PDGFR-BB is an inducer of mitotic proliferation in MKs. LOX inhibition with β-aminopropionitrile (BAPN) reduces PDGFR-BB binding to cells, and downstream signaling, as well as its proliferative effect on the MK lineage. Inhibition of LOX activity has no influence on MK polyploidy. We next rationalized that in a system with an abundance of low ploidy MKs, LOX could be highly expressed and with functional significance. Thus, we resorted to GATA-1 low mice, where there is an increase in low ploidy MKs, augmented levels of PDGF-BB, and an extensive matrix of fibers. MKs from these mice display high expression of LOX, compared to control mice. Importantly, treatment of GATA-1 low mice with BAPN significantly improves the bone marrow fibrotic phenotype, and MK number in the spleen. Thus, our in vitro and in vivo data support a novel role for LOX in regulating MK expansion by PDGF-BB, and suggest LOX as a new potential therapeutic target for myelofibrosis.
Lysyl oxidase (LOX) is a copperdependent amine oxidase that catalyzes the oxidative deamination of lysine and hydroxylysine residues on collagen and elastin precursors. The resulting semialdehydes form covalent cross linkages, thus stabilizing the extracellular matrix fiber deposits (1) . LOX is synthesized as a 50 kDa glycosylated precursor (pro-LOX) which is then secreted and undergoes proteolytic cleavage by pro collagen C-proteinases, including BMP1, to release a catalytically active 30 kDa enzyme (LOX) and an 18 kDa propeptide (LOX-PP) (2) (3) . LOX has been associated with various pathologies, including cardiovascular diseases (4), neurodegenerative disorders (5-6), tumor progression and metastasis (7) (8) (9) ). An interesting insight into the regulation of cellular proliferation by LOX came from a recent study, showing that LOX can oxidize and activate cell surface proteins, including PDGFR-β, in rat aortic smooth muscle cells (10) (11) . Nevertheless, the role of this oxidase in regulating megakaryocyte (MK) expansion and/or ploidy had not been explored.
Megakaryocytes (MKs), the platelet precursors, undergo proliferation followed by endomitosis and polyploidy, prior to fragmenting into platelets (12) (13) . In certain pathologies, the proliferation and ploidy of this lineage are deregulated, highlighting the need to further elucidate mechanisms of control of these processes (14-15). Thrombopoietin (TPO) is the primary growth factor that stimulates the proliferation, polyploidization and maturation of MK progenitors by activating c-mpl receptor signaling (16) . In addition to TPO, a number of cytokines are also involved in megakaryopoiesis (17) (18) (19) (20) . A number of studies have focused on the role of platelet-derived growth factor (PDGF) in megakaryopoiesis. PDGF was first isolated from human platelets as a protein with a molecular weight of 28-31 kDa, consisted of two polypeptide chains designated as A and B (21) . These two chains are linked together by disulphide bonds to form dimers (AA, AB, BB). Of these dimers, PDGF-BB binds to all known PDGF receptor isotypes (PDGFR-αα, -αβ, -ββ), and it possesses the strongest mitogenic activity (22) . Earlier studies with primary murine and human bone marrow cultures, as well as human umbilical cord blood CD34 positive cells have shown that PDGF-BB is a positive regulator of megakaryopoiesis (23) (24) (25) . Interestingly, PDGF-BB upregulates the expression of megakaryocyte-associated transcription factors, such as c-Fos, GATA-1 and NFE2 in megakaryocytic cell lines (26) . Considering the above-described effects of LOX on PDGF-R and of PDGF-BB on MKs, in this study we examined the expression of LOX in MKs and its potential roles in this lineage. We clearly demonstrated a downregulation of LOX as normal MKs become polyploid. Furthermore, LOX activity was found to be important for enhancing PDGF-mediated MK expansion via regulating Akt and ERK signaling. Additionally, we used a mouse model (GATA-1 low ) in which MK development is defective and one of the characteristics is an increased number of low ploidy MKs. In this model we showed that MKs have upregulated LOX levels. Interestingly, treatment of GATA-1 low mice with BAPN reduced marrow fibrosis, supporting a role for LOX in the progression of myelofibrosis. Our results suggest that LOX is a novel regulator of megakaryopoiesis via its effect on PDGFR-β, and a potential treatment target for primary myelofibrosis (PMF)
EXPERIMENTAL PROCEDURES
Mice: Wild type and GATA-1 low (ΔneoΔHS strain) (27) (28) hemizygote male mice were used for analysis (since mouse GATA gene is localized to X chromosome), as indicated. GATA-1 low mouse breeding pairs were kindly donated by Dr. John Crispino (Northwestern University). Wild type littermate males were used for comparison. Expansion of the mouse colony was performed at Boston University. When indicated, wild-type FVB mice were purchased from Taconic. All studies involving mice were approved by the Boston University Animal Care and Use committee.
TPO Injection: Tail vein injections of pegylated recombinant human Megakaryocyte Growth and Development Factor (PEG-rhMGDF, also known as TPO) were carried out as previously described (29) . Briefly, a stock solution of 55 mg/ml of PEG-rhMGDF was diluted in 1% normal mouse serum in PBS to a final concentration of 5 μg/ml PEG-rhMGDF. Each mouse received 100 μl per 10 g of body weight via tail vein injection. Control mice were injected with 1% normal mouse serum. Mice (FVB strain) were used for experiments three days post-injection were the effect of TPO on MK number and ploidy is maximal (30) .
BAPN treatment: β-aminopropionitrile (BAPN) was administrated in a dose of 150 mg/Kg BAPN ( Sigma, cat. A13134) dissolved in DPBS (Cellgro, cat. 21-0131-CV) and was injected intraeritoneally on a daily basis for a duration of 8 days in FVB wild type mice. Control mice received same volume of DPBS. Alternatively, on the fourth day post delivery, breast feeding mice were given drinking water containing 0.2% (wt/vol) BAPN as previously described (31) , for a duration of 10 weeks. 10.5 week-old mice were then used for analysis.
Bone marrow cultures:
Bone marrow from femurs, tibias and humeri was isolated as previously described (32) . Cells were cultured in IMDM media (Gibco, cat. 21056) containing 10% fetal bovine serum, 100 units/ml penicillin and 100 μg/ml streptomycin (Invitrogen, cat. 15070-063) or when indicated, in StemSpan serum free media (Stemcell, cat. 09650). Cells were treated either with 25 ng/ml PEG-rhMGDF (gift from Kirin Parma Company), 25 ng/ml PDGF-BB (R&D Systems, cat. 520-BB), or 100 μM BAPN or a combination or the above factors for a duration of three days prior to collection for downstream applications.
MK enrichment by Magnetic Activated Cell Sorting (MACS):
MKs were isolated from freshly derived bone marrow and cultured bone marrow cells for western blot and qRT-PCR analysis using the magnetic bead purification system as previously described (33) (34) and following manufacturer's instructions. MK purity was previously assessed at 83% based on FACS analysis (33) and no contamination from neutrophils or macrophages was found (34) . This percentage of purity is an underestimation considering the larger mass of polyploid MKs as compared to diploid cells.
Flow cytometry analysis of polyploidy:
Ploidy analyses were performed, based on CD41 antibody staining and propidium iodide DNA staining as previously described (35) . Flow cytometry was performed on a BD-FACSCalibur using a CellQuest software (BD Biosciences). o C and passed through a nylon mesh filter prior to sorting. MKs were sorted according to their DNA content using a MoFlo cytometer equipped with a 488 nm and a 351 nm laser and a 100 μM nozzle. A morphologic gate including all bone marrow cells was determined on a side scatter v forward scatter (SSC v FSC) dot plot. Cell aggregates were excluded via a Pulse width v FSC-height dot plot. FITC and Hoechst were assigned to FL1 and FL5 channels respectively. The sorting gates were determined on a FL1 v FL5 dot plot. CD41+ cells were sorted into 2N-4N and ≥8N cells at a rate of 3000 events/second.
Flow cytometry cell sorting:
Blood cell counts: Blood (0.5-0.6 ml) was collected via cardiac puncture. Blood was analyzed using the Hemavet multispecies hematology analyzer (Drew Scientific, Dallas, TX, cat. HV950FS) for complete blood count.
mRNA purification and transcript analysis: Homogenization of primary MKs was performed by using QiaShredder columns (Qiagen, cat. 79654) and RNA was isolated using the RNAeasy micro kit (Qiagen, cat. 74004). For cDNA synthesis, the QuantiTect Reverse transcription reaction kit was used (Qiagen, cat. 205310). Real time PCR was performed with the use of murine LOX (Mm00495386_m1) and murine GATA-1 (Mm00484678_m1) Taqman gene expression primers and probes (Applied Biosystems). Samples were run on an Applied Biosystems Sequence Detection System 7300. Data were normalized to GAPDH (Applied Biosystems, 4352339E) and analyzed using the ΔΔCT method.
Immunofluorescence: Mouse (FVB) bone marrow cells were cultured for three days in IMDM media, supplemented with 25 ng/ml TPO, 75 ng/ml MCSF (R&D Research, cat. 416-ML) and 10% FBS; conditions that induce development of mature and proliferating MKs. Next, cells were suspended in phosphate buffered saline (PBS) and centrifuged (3 x 10 5 cells/slide) to microscope slides (Fisher Scientific, cat. 12-550-15) using a Cytospin3 (Shandon) for 5 minutes at 120 x g. Cells were fixed in 4% paraformaldehyde at room temperature for 30 minutes and permeabilized with ice-cold 0.2% triton x-100 for 20 minutes. Cells were stained with rabbit polyclonal anti-LOX (36) and anti-rabbit Alexa 594 (Molecular Probes, cat. A21207). Slides were mounted with coverslips using Vectashield Mounting Medium for Fluorescence with 4,6 diamidino-2-phenylindole (DAPI). All slides were observed with an Olympus x70 inverted fluorescence microscope with a 40x objective. Images were documented with a Hamamatsu CCD camera (Hamamatsu photonics) and analyzed with ImagePro software (Media Cybernetics Inc).
Western blot analysis:
Cell pellets of primary MKs were lysed on ice with radioimmunoprecipitation assay buffer (1 xPBS, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS) supplemented with proteinase inhibitor cocktail (Roche, cat. 11697498001) and a phosphatase inhibitor cocktail (Roche, cat. 04906837001). Protein concentration was estimated with the Bradford protein assay (Bio-Rad, cat. 500-0006). SDS loading buffer was added to the protein lysate and was subjected to SDS-PAGE followed by a transfer to PVDF membranes at 30 V, overnight at 4 o C. The desired proteins were detected with rabbit anti-Akt (Cell Signaling, cat. 4685), rabbit anti AktS473 (Cell Signaling, cat. 9271), rabbit anti-p44/42 (ERK1/2) (Cell Signaling, cat. 4695S), rabbit anti-Pp44/42(T202/Y204) (Cell Signaling, cat. 4370S) and mouse monoclonal anti-β actin (Sigma, cat. A5441) that was used as an equal loading control.
Histology: Spleens and Femurs from 10.5 week-old mice were isolated and fixed in 10% (vol/vol) phosphate buffered formalin. Femurs were decalcified with 14% ethylenediaminetetra-acetic acid (EDTA, Boston Bioproducts, cat. BM-150) paraffin embedded and 3 μm sections were prepared. Slides were then stained with either hematoxylin (Fisher, cat. C5401-1D) -eosin stain (Sigma-Aldrich, cat. HT110132) or modified Gomori's stain for reticulin fibers (Scytek, cat. GRS-1). For quantitative measure of fibrosis, images of randomly chosen Gomori stained femur sections were acquired at 40X. ImageJ software (version 1.41o) was used to calculate the number of fibersfiber bands on gridded images covering an area of 0.5 mm 2 for each section. A total of three sections per mouse were processed. Standard deviations represent the mean of at least 5 mice per group. In spleen sections, the number of MKs was determined at x 200 original magnification in randomly chosen multiple sections to cover an area of 0.21 mm 2 per spleen from a total of three mice per group, based on similar methods described by (37) (38) (39) .
Statistical analysis: Statistical analysis was performed using the student's t-test, twosample equal variance (homoscedastic) with statistical significance at an α of at least 0.05.
RESULTS

LOX expression in megakaryocytes.
Bone marrow cells were stimulated with TPO for 0, 20, 96 hours and MKs were isolated post-treatment as described in methods. TPO downregulates the expression of LOX in the pool of MKs ( Figure  1A) . Similar results were shown in vivo, where murine bone marrow was harvested and MKs were isolated 3 days following tail vein injection with either TPO or vehicle ( Figure 1B ). This observed downregulation of LOX by TPO could be a result of reduced expression of this oxidase in the MK lineage all together, or perhaps owing to its differential expression in different ploidy MKs. Namely, since the majority of MKs in TPO-treated systems are of high ploidy, we tested the possibility that LOX is selectively downregulated in these cells. To this end, BM derived-MKs were sorted by FACS based on their ploidy level (Figure 2A) , and tested for LOX expression. The quality of the sorted fractions was confirmed by immunofluorescence microscopic analysis (Supplemental Figure 1) . As shown in Figure 2B , LOX is selectively expressed in 2N and 4N MKs. A potential regulation of LOX mRNA stability, or gene expression by transcription factors enriched in mature MKs, although not a focus of this study, is further described under Discussion. To further confirm these expression data at protein level, MKs were subjected to immunostaining using an antibody that recognizes the C-terminal domain of pro-LOX (36) . As shown in Figure 2C , pro-LOX is clearly detected in low ploidy MKs and no significant staining is noted in high ploidy MKs ( Figure 2C, panel II) .
.
LOX activity is important for MK expansion, but not polyploidy. To examine the functional significance of LOX expression in MKs, we tested whether inhibition of this enzyme by its known selective inhibitor, β-aminopropionitrile (BAPN) (40) affects MK ploidy in bone marrow cells. As shown in Figure  3 , LOX inhibition via intraperitoneal administration to mice does not affect the MK ploidy profile. Similar results were obtained when BAPN was added to bone marrow cultures (Supplemental Figure 2) . Inhibition of LOX by BAPN was confirmed using methods described in (41-42) (Supplemental Figure 3) . These results suggest that LOX activity is not needed for induction of MK ploidy. Considering that LOX activity is important for binding of PDGF to its receptor, via PDGF receptor oxidation (10) , and that PDGF has an inducing effect on expansion of the MK lineage (23, 25) , we tested whether LOX activity plays a role in PDGF-induced increase in MK number. As shown in Figure 4 , PDGF has a significant stimulating effect on MK number, which is all abolished by BAPN-mediated inhibition of LOX. This effect is corroborated by Western blot analysis of MKs using antiProliferating Cell Nuclear Antigen (PCNA), a widely know marker for cellular proliferation (Supplemental Figure 4) . In addition, LOX inhibition resulted in downregulation of PDGFinduced Akt phosphorylation, as well as ERK1/2 phosphorylation ( Figure 5 ). This further supports a role for LOX activity in PDGF-mediated MK lineage development, as these signaling pathways are important for MK expansion (43) (44) . In accordance, LOX inhibition reduces the binding of PDGF-BB to MK-enriched cultures (Supplemental Figure 5 ).
LOX activity is important for bone marrow matrix deposition.
In view of the newly identified expression of LOX in normal, low DNA content MKs (Figure 2 ) and its role in matrix deposition, we next sought to examine the expression of LOX in a system where low-ploidy MKs are abundant, and the matrix is pathological. GATA-1 low mice are characterized by a targeted mutation of regulatory elements upstream to the GATA-1 locus, which leads to decreased expression of GATA-1 in the MK lineage, resulting in an increased number of low DNA content MKs and thrombocytopenia (45) (46) , as also confirmed in our studies ( Figure 6A -C, Supplemental Table 1 ). Intriguingly, LOX expression was found to be upregulated in MKs derived from GATA-1 low mice, as compared to control mice ( Figure 6D ) by approximately 2.5-fold, similarly to a 2.3-fold increase in the percentage of low ploidy (2N-4N) MKs. As MK number increases, they generate and release greater levels of PDGF, which is also the case for GATA-1 low mice (38, 47) . To test whether inhibition of LOX has the potential to attenuate MK number and matrix deposition in vivo, wild type and GATA-1 low mice (age-gender-and strain-matched) were provided with drinking water containing 0.2% (wt/vol) BAPN as described in methods. The specific dose of BAPN treatment was chosen based on previous studies (31), which showed effective LOX inhibition with no side effects on survival or growth. This was further confirmed in our system (Supplemental Figure  6A) . The mouse spleen is a known resident of abundant MKs in GATA-1 low mice (38) , also characterized by splenomegaly ( Figure 7A ). Treatment of these mice with BAPN did not alter the spleen size, but significantly reduced the number of MKs ( Figure 7B-C) . Detection of MKs in these sections was based on the large nucleus size and morphology, and confirmed by immunohistochemistry using a CD41 antibody, which marks MKs (Supplemental Figure 7 ). These differences, however, were not sufficient to elicit significant changes in platelet number (Supplemental Table 2 ), which is in line with other systems where platelet level is less influenced by moderate changes in MK number. Mild effect of this dose of BAPN on MK number in vivo could be due to accumulation of proliferation-inducing factors, other than PDGF (48), such as vascular endothelial growth factor (VEGF) and fibroblast growth factor-A in the MK microenvironment (38, 47) . In accordance with the primary culture data (Figure 3 ), BAPN-treated wild type and GATA-1 low mice did not show a significant change in the ploidy level of bone marrow MKs, as judged by flow cytometry analysis (Supplemental Figure  6B) .
Finally, we examined the contention that LOX might also be an important regulator of MKinduced bone marrow fibrosis. Fibers are formed as result of LOX-mediated cross linking of matrix proteins, including collagen (49) . A hallmark of myelofibrosis in GATA-1 low mice is the progressive accumulation of fibers within the bone marrow. Fibrosis alters the bone marrow structure that results in abnormal trafficking of progenitor cells, eventually leading to extramedullary hematopoiesis (48) . As shown in Gomori's silverstained femur sections ( Figure 8A,B) , 0.2% (wt/vol) BAPN treatment improves the fibrotic phenotype of GATA-1 low mice by reducing the fibers by 37 % as compared to non-treated mice. Wild type mice were also treated, and as expected, no fibers were detectable in either control or BAPN-treated mice. Hematoxylin-eosin stained sections did not reveal a significant change in MK number in the bone marrow upon BAPN treatment (see legend to Figure 8A ), which was further confirmed by FACS analysis (not shown). This is possibly due to the fact that a large percentage (approximately 30-40%) of GATA-1 low bone marrow MKs are already in the process of paraapoptotic death (characterized by heterochromatic area surrounding the nucleoli and cytoplasmic vacuoles originated by dissolution of granules) (50) . The BAPN-mediated reduction in reticulin fibers supports a role for LOX in the progression of myelofibrosis, and represents the first application of LOX for remedy of such bone marrow pathology. The potential of this regime is enhanced by the fact that hematological parameters were essentially not significantly altered by LOX inhibition (Supplemental Table 2 ).
DISCUSSION
MK differentiation involves a variety of cytokines and transcriptions factors. PDGF was demonstrated by a number of in vitro studies to promote MK lineage expansion via upregulation of transcription factors crucial to MK development such as GATA-1 and NFE2 (26) . The importance of this cytokine also stemmed from studies showing that PDGF-B knockout mice are thrombocytopenic (51) . Therefore, understanding the molecular events that regulate PDGF-mediated signaling will provide a better understanding of pathological conditions where MK differentiation is defective. In search for novel regulators of PDGF, we recently found that LOX affects the binding of PDGF to PDGFR-β in vascular smooth muscle cells, and subsequently enhance downstream proliferation signaling (10).
The present study explored the potential role of LOX in MK expansion and the underlying molecular mechanisms regulated by this oxidase. Our data indicate that LOX is produced by low ploidy MKs, while downregulated in the highploidy ones, and that TPO significantly attenuates LOX expression both ex vivo and in vivo in a total pool of MKs. This suggests that low dose of TPO administration results with low detection of LOX by increasing the number of polyploid MKs. Of note, high doses of TPO administration (500 μg/Kg) for a prolonged period of time were shown to induce bone marrow fibrosis (52) . It is likely that overproliferation of MKs in the TPO high model (52) Figure 8) . GATA-1 binding sites are also predicted in other members of the LOX family (54) (55) . On the other hand, the LOX gene promoter also contains putative binding sites for Runx-1, a transcription factor enriched in mature MKs, also known to inhibit or stimulate gene expression, depending on neighboring sequences (Supplemental Figure 8) . Future studies will focus on the mechanisms by which the LOX gene is potentially downregulated by transcription factors enriched in mature MKs.
Having determined the MK expression pattern of LOX during MK development, we next sought to investigate its effect on PDGF-mediated MK expansion. We resorted to using a pharmacological irreversible inhibitor of LOX. BAPN, , has been frequently used to investigate the catalytic activity of this enzyme (10, 45, 56) . The concentration of BAPN used in this study (100 μM) has been previously shown to be selective for LOX among a wider group of amine oxidases (40) . Our results clearly demonstrate that inhibition of LOX by BAPN ablates the effect of PDGF on MK expansion, as well as PDFG eminent signaling. This would be expected based on the previously described ability of LOX to oxidize the PDGF receptor and consequently amplify downstream signaling (10) .
The functional relevance of LOX expression in MKs is beyond PDGF-induced cellular proliferation; it expands to matrix deposition. This was shown by examining the levels and function of LOX in a mouse model for myelofibrosis, As previously stated, GATA-1 low mice are thrombocytopenic, with increased frequency of MKs in the bone marrow (45) . Their MKs are abnormal, with low ploidy, as their proper differentiation is halted due to a mutation in the GATA-1 promoter that results in MK restricted downregulation of GATA-1 (ΔneoΔHS strain) (45) . Interestingly, LOX expression is upregulated in GATA-1 low MKs as compared to wild type, consistent with the differential expression of LOX in 2N-4N MKs. Importantly, LOX inhibition significantly reduced the number of MKs in the spleen of GATA-1 low mice as well as improved their fibrotic phenotype, further affirming a role for LOX in the development of myelofibrosis. Of note, LOX is also highly detected in patient-derived megakaryoblastic cell lines, and in the BM blasts of 9 out of 11 patients suffering from non DS-AMKL (57) (data deposited at www.ncbi.nlm.nih.gov/geo; GEO accession no. GSE4119).
In summary, for the first time, our study provides a link between LOX, PDGF and PDGFmediated MK propagation. Our findings support a mechanism where under physiological conditions TPO induces MK polyploidy and, hence, keeps LOX at low levels, which is dispensable for polyploidization. Importantly, LOX is remarkably upregulated in MKs in pathological condition, such as myelofibrosis, and LOX inhibition significantly attenuates this pathology. Data were normalized to GAPDH mRNA. MK purity was evaluated as described in methods. B. In vivo effect of tail vein injections of 5 μg/Kg TPO in wild-type mice. Bone marrow was extracted 3 days post-injection and MKs were isolated for qRT-PCR analysis. Effects of TPO on MK ploidy and platelet counts were confirmed as in (29) . Standard deviation bars represent the mean of three independent experiments, *p<0.05. qRT-PCR analysis for LOX and GATA-1 (a marker for MK differentiation) on MK sorted fractions. Data were normalized to GAPDH mRNA. N.D=not detected. Standard deviation bars represent the mean of four independent experiments, *p<0.05. C. Staining of low and high ploidy MKs with anti-LOX. Cells were prepared as described in methods. DNA was stained with DAPI (blue) to be able to distinguish between typical low ploidy (2N-4N) and high ploidy (≥8N) cells, based on DNA density compared to diploid bone marrow cells, and evaluated as we described in (58) . Immunostaining was performed using rabbit IgG as control and 594 Alexa anti-rabbit secondary antibody to test for antibody specificity (panel I). Panel II: The white arrow depicts a low ploidy MK with pro-LOX staining (red). Within the same field and preparation, a yellow arrow depicts a high ploidy MK with no (or very dim) pro-LOX staining. Data shown represent at least ten slides analyzed, each with about 10 5 cytospin cells, from two different experiments. low , control or BAPN-treated mice (10.5 week old at the time of collection), as described in Methods. Original magnification for left column is 400X and for the right column is 600X. Arrows indicate the large presence of MKs (H&E stain) and the accumulation of reticulin fibers (Gomori) in the GATA-1 low mice. As expected, no such fibers are detected in wild type mice. Counting morphologically recognizable MKs in 8 sections per mouse, using histological approaches described earlier (37) (38) (39) showed no significant differences in MK number in bone marrow sections of control and BAPN-treated mice. Similar results were obtained in a total of 5 mice per group. MK counting was further confirmed by flow cytometry analysis as in Figure 3 (data not shown) . 
